Pravastatin transdermal patch: Effect of the formulation and length of microneedles on in- vitro percutaneous absorption studies.

Document Type : Short Comunication

Authors

1 Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Unidad de Investigación Multidisciplinaria. Laboratorio 12: Sistemas Transdérmicos Carretera Cuautitlán Teoloyucan, km 2.5 San Sebastián Xhala C.P 54714 Cuautitlán Izcalli, Estado de México.

2 Universidad Autónoma Metropolitana-Departamento de Sistemas Biológicos. UAM-Xochimilco. Calzada del Hueso 1100. Colonia Villa Quietud. C.P. 04960. Ciudad de México.

3 Hospital Regional de Alta Especialidad de Zumpango. Unidad de Enseñanza e Investigación. Zumpango Edo. de Méx. Carretera Zumpango-Jilotzingo #400. Barrio de Santiago 2da Sección. Zumpango, Estado de México. C.P. 55600.

Abstract

Transdermal patches loaded with pravastatin was previously characterized in another published study by Serrano-Castañeda et al; 2015. These transdermal patches (TP) were generated by the plate casting technique, the in vitro percutaneous absorption studies of TP were evaluated for three different formulations of TP with different quantities of Pluronic F-127 (PF-127): i) without PF-127 (TP W), ii) 1% of PF-127 (TP 1%), and iii) 3% of PF-127 (TP 3%) and using solid microneedles as a penetration enhancer with two different lengths: i) 0.25mm and ii) 2.25mm and iii) in vitro permeation studies without using microneedles on TP. The fluxes (F), time lag (tLag) and permeability constants (kp) for each formulation were: TP W (F:38.5µg/cm2*h, tLag:18.97h and kp:5.9x10-3cm/h), TP W with microneedles of 0.25 mm (F:103.3 µg/cm2*h, tLag: 20.76 h and kp: 0.0158 cm/h), TP W and microneedles of 2.25 mm (F:105.2µg/cm2*h, tLag: 21.16 h and kp: 0.0159cm/h), TP 1% (F:90 µg/cm2*h, tLag: 19.48 h and kp: 0.0137 cm/h), TP 1% with microneedles of 0.25 mm (F:111.4µg/cm2*h, tLag:19.11h and kp:0.017cm/h), and TP 1% with microneedles of 2.25 mm (F:115.2µg/cm2*h, tLag:16.73h and kp:0.017cm/h), TP 3% (F:40.9µg/cm2*h, tLag:20.45h and kp:0.0062 cm/h), TP 3% with microneedles of 0.25 mm (F:67.1 µg/cm2*h, tLag: 21.79h and kp:0.0102cm/h) and TP 3% with microneedles of 2.25 (F:70.5 µg/cm2*h, tLag:20.44h and kp:0.0107cm/h). Results show that the formulation of TP affects the pravastatina flux and kp parameters, however the length of microneedles only has important effect on time lag (tLag).

Graphical Abstract

Pravastatin transdermal patch: Effect of the formulation and length of microneedles on in- vitro percutaneous absorption studies.

Keywords

Main Subjects

References

  1. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Disop. 2010; 38: 92-99.
  2. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-77.
  3. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P. The Pharmacogenetics and Pharmacodynamics of Clopidogrel ResponseAn Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial. JACC Cardiovasc Interv 2008; 1: 620-27.
  4. Jeong Y-H, Kim I-S, Park Y, Kang M-K, Koh J-S, Hwang S-J, Kwak CH, Hwang J-Y. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/dayResults of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010; 3: 731-41.
  5. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 89-94.
  6. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
  7. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart, Lung and Circulation 2007; 16: S17-S28.
  8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Variability in Platelet Aggregation Following Sustained Aspirin and Clopidogrel Treatment in Patients With Coronary Heart Disease and Influence of the 807 C/T Polymorphism of the Glycoprotein Ia Gene. The Am J of Cardiol. 2005; 96: 1095-99.
  9. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-75.
  10. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
  11. Suh J-W, Koo B-K, Zhang S-Y, Park K-W, Cho J-Y, Jang I-J, Lee D-S, Sohn D-W, Lee M-M, Kim H-S. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J 2006; 174: 1715-22.
  12. Pettersen A-AR, Arnesen H, Opstad TB, Seljeflot I. The influence of CYP 2C19* 2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thrombosis journal 2011; 9: 4.
  13. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet 2010; 376: 1312-19.
  14. Li Y-H, Wang Y-H, Li Y, Yang L. MDR1 Gene Polymorphisms and Clinical Relevance. Acta Genetica Sinica 2006; 33: 93-104.
  15. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 1987; 84: 7735-38.
  16. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-70.
  17. Namazi S, Kojuri J, Khalili A, Azarpira N. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochem Pharmacol 2012; 83: 903-08.
  18. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Bañuelos C, Hernández-Antolín R, Escaned J, Moreno R, Alfonso F. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-10.
  19. MÜLLER I, SEYFARTH M, RÜDIGER S, WOLF B, POGATSA-MURRAY G, SCHÖMIG A, GAWAZ M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
  20. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn H-P, Büttner HJ, Neumann F-J. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-64.
  21. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, ten Berg JM, Neumann F-J, Bollwein H, Dirschinger J, Schömig A. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44: 2133-36.
  22. Namazi S, Khalili A, Kojuri J, Azarpira N. The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention. J of Clin Pharmacol. 2012;52(7):1098-105.
  23. Su J, Xu J, Li X, Zhang H, Hu J, Fang R, Chen X. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 2012; 7: e46366.
  24. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010; 79: 921-25.
  25. Nakamura T, Sakaeda T, Ohmoto N, Tamura T, Aoyama N, Shirakawa T, Kamigaki T, Nakamura T, Kim KI, Kim SR. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 2002; 30: 4-6.
  26. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002; 25: 1356-9.
  27. Lacy C, Armstrong L, Goldman M, Lance L. Lexicomp. Drug Information Handbook with International Trade Names Index 20nd ed: Lexi-Comp, 2011-2012.
  28. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
  29. Gasparyan AY, Watson T, Lip GY. The Role of Aspirin in Cardiovascular PreventionImplications of Aspirin Resistance. J Am Coll Cardiol 2008; 51: 1829-43.
  30. Gent M, Beaumont D, Blanchard J, Bousser M, Coffman J, Easton J, Hampton J, Harker L, Janzon L, Kusmierek J. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. The Lancet 1996; 348: 1329-39.
  31. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
  32. Wiviott SD, Antman EM. Clopidogrel resistance a new chapter in a fast-moving story. Circulation 2004; 109: 3064-67.
  33. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of Body Mass Index on Platelet Aggregation After Administration of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous Coronary Intervention. The Am j of cardiol. 2007; 100: 203-05.
  34. Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009; 158: 784. e1-84. e6.
  35. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary InterventionThe Role of Dual Drug Resistance. J Am Coll Cardiol 2006; 47: 27-33.
  36. Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009; 5: 989-1004.
  37. Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schömig A, Kastrati A. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010; 31: 1205-11.
  38. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
  39. Azarpira N, Aghdaie M. Frequency of C3435 MDR1 and A6896G CYP3A5 single nucleotide polymorphism in an Iranian population and comparison with other ethnic groups. Medical Journal of The Islamic Republic of Iran (MJIRI) 2006; 20: 131-36.
  40. Shalia KK, Shah VK, Pawar P, Divekar SS, Payannavar S. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response. Indian Heart J 2013; 65: 158-67.
  41. Xie H-G, Kim RB, Wood AJ, Stein CM. molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.
  42. Mizutani T. PM Frequencies of Major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99-106.
  43. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. P Natl Acad Sci. 2000; 97: 3473-78.
  44. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GDV, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010; 79: 921-25.
  45. Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res 2013; 132: 81-87.
  46. Luo M, Li J, Xu X, Sun X, Sheng W. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis. Thromb Res 2012; 129: 754-59.
  47. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet; 376: 1312-19.
  48. Karaźniewicz-Łada M, Danielak D, Rubiś B, Burchardt P, Komosa A, Lesiak M, et al. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2014:n/a-n/a.
  49. Wang X-q, Shen C-l, Wang B-n, Huang X-h, Hu Z-l. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. Available online 24 December 2014, ISSN 0378-1119, http://dx.doi.org/10.1016/j.gene.2014.12.051.
  50. Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. Mol Biol Rep 2014; 41: 331-36.
  51. Jeong H-E, Lee S-J, Cha E-Y, Kim E-Y, Kim H-S, Song YH, Shin J-G. Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel. Intl j of mol sci. 2014; 15: 7699-710
Iranian Journal of Pharmaceutical Research
Volume 19, Issue 2
Spring 2020
Pages 127-133

Files

Share

How to cite

Statistics